Targeting KRAS in cancer - Nature Medicine
2024年4月18日 · The first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents—sotorasib and adagrasib ...
KRAS mutations in advanced non-small cell lung cancer: From …
Kristen rat sarcoma viral oncogene homolog (KRAS) mutations play a major role in the carcinogenesis of many types of solid tumors including non-small cell lung cancer (NSCLC). Among KRAS mutations, p.G12C single-nucleotide variant (KRAS G12C) is the most
Targeting KRASG12D mutation in non-small cell lung cancer: …
2024年5月11日 · Ruess et al. found that PTPN11 gene deletion significantly inhibited tumor development in KRAS-driven pancreatic ductal adenocarcinoma and non-small cell lung cancer mouse models, providing...
KRAS and Lung Cancer
2024年9月26日 · An error in the KRAS gene is one type of lung cancer biomarker. It is called KRAS because it was first identified as causing cancer in Kirsten rat sarcoma virus. There are other types of RAS mutations, but right now, targeted treatment is only available for KRAS in patient withs lung cancer and specifically for one type of KRAS mutation called ...
Overcoming KRAS -Mutant Lung Cancer - ASCO Publications
2022年4月12日 · KRAS-driven lung cancer is a distinct biologic subtype of non–small cell lung cancer that is associated with favorable responses to immune checkpoint blockade therapy. Direct KRAS G12C inhibitors lock KRAS G12C in the off state by binding to a state-specific allosteric pocket of the mutant enzyme.
Targeting KRAS in non-small-cell lung cancer: recent progress and …
2021年6月1日 · In this article, we discuss the biology and history of targeting KRAS in lung cancer and provide an update on these emerging therapies. KRAS biology: structure, function, and downstream effector pathways
Current perspectives of KRAS in non-small cell lung cancer
2024年8月1日 · Focused and communal efforts made by the scientific community to improve lung cancer prognosis, including but not limited to smoking awareness and cessation, widespread lung cancer screening in smokers 1 leading to increased incidence of stage I NSCLC diagnoses, 2 and targeted treatment 3 and the advent of immunotherapy 4 have led to ...
Decoding KRAS mutation in non-small cell lung cancer patients …
6 天之前 · We evaluated 143 patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS mutations. The most common mutation was G12C (41 %), followed by G12V (23.7 %) and G12D (11.8 %). The G12C mutation was notably associated with a higher incidence of bone metastases (42 %). Immunotherapy was administered as monotherapy in 54.5 % of …
KRAS mutation: from undruggable to druggable in cancer
2021年11月15日 · There is growing evidence that KRAS (G12C), KRAS (G12V), KRAS (G12D), and KRAS (G13D) mutations are associated with high PD-L1 expression in lung cancer 100,101.
KRAS-Mutant Lung Cancer: Targeting Molecular and …
We found that blocking IL-1β with an IL-1β mAb in a KRAS-G12D-mutant mouse model of lung cancer led to tumor regression, which was associated with increased infiltration of CD8+ T cells, potentially due to a decrease in myeloid-cell-associated immunosuppression as well as inhibition of the NF-kB and STAT3 pathways .